intraocular-pressure
(3)
Avisi Technologies
Avisi Technologies is a clinical-stage ophthalmic medical device company building VisiPlate, an ultrathin, nanotechnology-enabled aqueous shunt that drains excess fluid from the eye to lower pressure in glaucoma patients. Spun out of the University of Pennsylvania's Y-Prize program in 2017, the company is advancing VisiPlate through the FDA-cleared SAPPHIRE pivotal trial and has raised roughly $21.7M to date, including a $10.7M Series A in February 2026.
QURA, Inc.
QURA, Inc. is a preclinical medical-technology company in Massachusetts building a tiny implanted sensor that continuously measures blood pressure and wirelessly transmits medical-grade waveform data to patients and physicians in real time. Its QSmart platform - a vitamin-sized QSense implant paired with software and analytics - aims to replace the occasional cuff reading with always-on monitoring, targeting hypertension, the leading cardiovascular risk factor worldwide. The technology grew out of an earlier wireless implantable pressure sensor developed for glaucoma (intraocular pressure) monitoring.
ViaLase, Inc.
ViaLase, Inc. is a clinical-stage medical technology company in Aliso Viejo, California building the first femtosecond laser designed to treat primary open-angle glaucoma without cutting into the eye. Its ViaLuxe Laser System pairs micron-level, high-definition imaging with a femtosecond laser to perform a noninvasive, image-guided trabeculotomy - branded FLigHT - that creates a drainage channel through the trabecular meshwork to lower intraocular pressure. Founded in 2019 by femtosecond-laser pioneer Tibor Juhasz, the company has raised more than $115 million, earned a CE Mark in Europe, and begun a U.S. IDE clinical trial.